Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SCH 58500||p53 Gene Therapy 4||SCH 58500 is a recombinant adenoviral vector encoding wild-type human TP53 that may introduces TP53 into tumor cells, leading to tumor cell apoptosis (PMID: 12082455).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||SCH 58500||Phase Ib/II||Actionable||In a Phase I/II trial, SCH 58500 demonstrated safety and preliminary efficacy, resulted in measurable transgene expression in 85% (17/20) of biopsy samples, and more than 50% reduction of CEA level in 50% (8/16) of ovarian cancer patients who received three cycles of treatment (PMID: 12082455).||12082455|
|Unknown unknown||ovarian cancer||not applicable||SCH 58500||Phase I||Actionable||In a Phase I trial, treatment with multiple doses of SCH 58500 in combination with chemotherapy resulted in a median survival of 12-13 months in heavily pretreated ovarian cancer patients, with 10 patients surviving more than 20 months (PMID: 12082456).||12082456|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|